Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.47 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5059161 | 0.98 | EGFR (0.53) | EGFRALDH1A1SMN1; SMN2SIGMAR1MAPK1 | |
| SCHEMBL25421283 | 0.98 | EGFR (0.53) | EGFRALDH1A1SMN1; SMN2SIGMAR1MAPK1 | |
| Hydrochloric Acid SCHEMBL21814218 | 0.98 | EGFR (0.56) | EGFRALDH1A1SMN1; SMN2SIGMAR1MAPK1 | |
| SCHEMBL3422030 | 0.98 | EGFR (0.53) | EGFRALDH1A1SMN1; SMN2SIGMAR1MAPK1 | |
| Bromide SCHEMBL14247934 | 0.97 | EGFR (0.52) | EGFRALDH1A1SMN1; SMN2SIGMAR1MAPK1 | |
| Bromide SCHEMBL28444822 | 0.97 | EGFR (0.52) | EGFRALDH1A1SMN1; SMN2SIGMAR1MAPK1 | |
| SCHEMBL10317072 | 0.94 | ALDH1A1 (0.54) | EGFRALDH1A1SMN1; SMN2SIGMAR1MAPK1 | |
| SCHEMBL25134221 | 0.94 | EGFR (0.50) | EGFRALDH1A1SMN1; SMN2SIGMAR1MAPK1 | |
| SCHEMBL17921386 | 0.92 | EGFR (0.48) | EGFRALDH1A1SMN1; SMN2SIGMAR1MAPK1 | |
| SCHEMBL5054607 | 0.92 | EGFR (0.48) | EGFRALDH1A1SMN1; SMN2SIGMAR1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4747248-A1 | COMPOUNDS FOR USE IN A METHOD OF TARGETED PROTEIN DEGRADATION | Institute of Cancer Research: Royal Cancer Hospital (The) (GB) | 2026-05-27 | — | — | EP | disclosed |
| US-12312316-B2 | Compounds and methods for the targeted degradation of androgen receptor | ARVINAS OPERATIONS, INC. (US) | 2025-05-27 | — | — | US | disclosed |
| WO-2025022093-A1 | COMPOUNDS FOR USE IN A METHOD OF TARGETED PROTEIN DEGRADATION | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2025-01-30 | — | — | WO | disclosed |
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | ARVINAS OPERATIONS, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-20230373999-A1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2023-11-23 | — | — | US | disclosed |
| US-20230365562-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-11-16 | — | — | US | disclosed |
| US-20230365563-A1 | QUINAZOLINE COMPOUND AND APPLICATION THEREOF | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2023-11-16 | — | — | US | disclosed |
| US-11807636-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-20230286955-A1 | INHIBITORS OF THEM1 | TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTE | 2023-09-14 | — | — | US | disclosed |
| US-20230242541-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | UPPTHERA, INC. (KR) | 2023-08-03 | — | — | US | disclosed |
| WO-1998042656-A1 | NOVEL COMPOUNDS | CYTEL CORPORATION (US) | 1998-10-01 | — | — | WO | disclosed |
| EP-0800516-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS HAVING SUBSTITUTED (b)-AMINO ACID RESIDUES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | NIPPON STEEL CORPORATION (JP) | 1997-10-15 | — | — | EP | disclosed |
| US-5614535-A | Adhesion receptor antagonists | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1997-03-25 | — | — | US | disclosed |
| EP-0741133-A2 | Adhesion receptor antagonists | MERCK PATENT GmbH (DE) | 1996-11-06 | — | — | EP | disclosed |
| EP-0551993-B1 | Pyrrolidine derivatives and process for preparing the same | SUMITOMO PHARMA (JP) | 1996-07-10 | — | — | EP | disclosed |
| WO-1996020172-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS HAVING SUBSTITUTED β-AMINO ACID RESIDUES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | NIPPON STEEL CORPORATION (JP) | 1996-07-04 | — | — | WO | disclosed |
| CN-1125575-A | Adhesion receptor antagonists | MERCK PATENT GMBH (DE) | 1996-07-03 | — | — | CN | disclosed |
| US-5532255-A | Adhesion receptor antagonists | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1996-07-02 | — | — | US | disclosed |
| US-5322952-A | Pyrrolidine derivatives and process for preparing the same | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1994-06-21 | — | — | US | disclosed |
| EP-0551993-A1 | Pyrrolidine derivatives and process for preparing the same | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1993-07-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230286955-A1 | INHIBITORS OF THEM1 | GOT1, GOT2, FAR1 | EGFR 4545/4885ALDH1A1 2838/4885SMN1; SMN2 1979/4885 |
| US-20230365562-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | EGFR 1156/4885ALDH1A1 2776/4885SMN1; SMN2 2647/4885 |
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | IRAK1, IRAK4, IRAK2 | EGFR 349/4885ALDH1A1 2211/4885SMN1; SMN2 1811/4885 |
| US-12312316-B2 | Compounds and methods for the targeted degradation of androgen receptor | AR, MDM2, ESRRA | EGFR 190/4885ALDH1A1 514/4885SMN1; SMN2 4607/4885 |
| US-20230365563-A1 | QUINAZOLINE COMPOUND AND APPLICATION THEREOF | KRAS, NRAS, BRAF | EGFR 950/4885ALDH1A1 3174/4885SMN1; SMN2 2665/4885 |
| US-11807636-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | EGFR 1156/4885ALDH1A1 2776/4885SMN1; SMN2 2647/4885 |
| US-20230242541-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | PLK1, BUB1B, BUB1 | EGFR 2445/4885ALDH1A1 4008/4885SMN1; SMN2 3089/4885 |
| US-20230373999-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | EGFR 229/4885ALDH1A1 3370/4885SMN1; SMN2 4385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.